0 324

Cited 2 times in

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION

DC Field Value Language
dc.contributor.author김성훈-
dc.contributor.author이정윤-
dc.date.accessioned2019-12-18T01:11:51Z-
dc.date.available2019-12-18T01:11:51Z-
dc.date.issued2019-
dc.identifier.issn0368-2811-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/173412-
dc.description.abstractA pilot study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer has been started in Korea. Archival tumor samples were tested for HRD and PD-L1 status. Treatment arms will be allocated according to the test results. For HRD+ patients, we tested the synergistic effects of olaparib and other agents; treatment arms will randomly be allocated. (Arm 1: olaparib and cediranib; Arm 2: olaparib and durvalumab). For HRD- patients, we tested the role of biomarker-driven immunotherapy according to PD-L1 expression (Arm 3: durvalumab and chemotherapy in patients with high PD-L1 expression; Arm 4: durvalumab, tremelimumab, and chemotherapy in patients with low PD-L1 expression). Sixty-eight patients will be included from three Korean institutions within 1 year. The primary endpoint is the response rate according to RECIST 1.1 (6 months after treatment initiation). This trial has been registered with clinicaltrials.gov, and the registration number is NCT03699449.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfJAPANESE JOURNAL OF CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleAn umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Obstetrics and Gynecology (산부인과학교실)-
dc.contributor.googleauthorJung-Yun Lee-
dc.contributor.googleauthorJu Yeon Yi-
dc.contributor.googleauthorHyun-Soo Kim-
dc.contributor.googleauthorJune Lim-
dc.contributor.googleauthorSunghoon Kim-
dc.contributor.googleauthorByoung Ho Nam-
dc.contributor.googleauthorHee Seung Kim-
dc.contributor.googleauthorJae Weon Kim-
dc.contributor.googleauthorChel Hun Choi-
dc.contributor.googleauthorByoung-Gie Kim-
dc.identifier.doi10.1093/jjco/hyz085-
dc.contributor.localIdA00595-
dc.contributor.localIdA04638-
dc.relation.journalcodeJ01207-
dc.identifier.eissn1465-3621-
dc.identifier.pmid31671191-
dc.identifier.urlhttps://academic.oup.com/jjco/article/49/8/789/5523680-
dc.subject.keywordbiomarker-
dc.subject.keywordovarian cancer-
dc.subject.keywordplatinum-resistant-
dc.subject.keywordtargeted therapy-
dc.subject.keywordumbrella study-
dc.contributor.alternativeNameKim, Sung Hoon-
dc.contributor.affiliatedAuthor김성훈-
dc.contributor.affiliatedAuthor이정윤-
dc.citation.volume49-
dc.citation.number8-
dc.citation.startPage789-
dc.citation.endPage792-
dc.identifier.bibliographicCitationJAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.49(8) : 789-792, 2019-
dc.identifier.rimsid63927-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.